Close

Abzena appoints Jim Kennamer as SVP and Site Head of North Carolina

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...
- Advertisement -

Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Jim Kennamer as Senior Vice President and Site Head of North Carolina.

With over 30 years’ experience in the Pharmaceutical industry, Jim has held various positions with increasing levels of responsibilities at Boehringer Mannheim Biochemical, Roche Molecular Biochemicals, Diosynth, Strategene, and Talecris Biotherapeutics/Grifols Therapeutics. For the past six years he has been the Vice President of Global Manufacturing Operations for Immucor in Norcross Georgia.

Jim has deep experience with manufacturing operations and processes, particularly in process improvements. He has driven regulatory compliance and audit readiness for multiple regulatory agencies, established complex supply agreements, and has driven LEAN and right first-time operations throughout his organizations. Jim previously sat on the North Carolina State University Biotechnology Training and Education Center (BTEC) Advisory Board.

Jim has a Bachelor of Science Degree in Biochemistry from Oklahoma State University in Stillwater, Oklahoma and a Doctor of Philosophy, Biochemistry also from Oklahoma State University.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...

Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351

Japan-based Chugai Pharmaceutical has entered into an exclusive license...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »